Adolescent, Child, Crohn Disease, Diet, Enteral Nutrition, Remission
Conditions
Brief summary
The primary objective of this study is to determine the efficacy of a novel enteral nutrition (EN) protocol (delivering 75% of patient's caloric needs through EN) for induction of remission in patients with active childhood-onset Crohn's disease (CD) and compare it to the standard protocol with exclusive enteral nutrition (EEN). This novel approach allows patients to consume remaining calories (25%) from an antiinflammatory diet for CD (AID-CD). The hypothesis is that no significant difference in the remission rate between the novel EN protocol with partial enteral nutrition (PEN) and standard protocol with EEN will be observed.
Detailed description
Background: Exclusive enteral nutrition (EEN) is a well established method of treatment for inducing remission in childhood-onset Crohn's disease. It involves placing children on a strict diet composed only of a single polymeric formula, as the sole source of nutrition over 6 to 8 weeks. Use of this treatment method results in clinical remission in 50% to 80% of children by week 6-8. Partial enteral nutrition (PEN) would be more acceptable to patients than EEN, and might be an effective treatment for active Crohn's disease. Moreover, there are studies suggesting that PEN may be effective for the induction of remission in pediatric patients with Crohn's disease; however, the level of evidence is still low. Methods: This is a prospective randomized controlled trial, in patients with active childhood-onset Crohn's disease comparing two arms over 6 weeks of therapy. Group 1 (PEN group): will receive 75% of their dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) whole food AID-CD for 6 weeks. Group 2 (EEN group): will receive EEN with Alicalm (Nutricia) for 6 weeks. Patients will be seen at onset and week 1, 3, and 6. This study will evaluate clinical response (a decrease in PCDAI score of ≥12.5 points), clinical remission (PCDAI \<10) and mucosal healing using SES-CD in both groups, as well as the effects of the two nutritional approaches on the patients' nutritional status. Antiinflammatory diet for Crohn's disease (AID-CD) is based on reducing exposure to animal fat, simple carbohydrates and processed food. We removed foods that previous research has shown to induce inflammation and added foods that have been shown to be beneficial in reducing inflammation. Our AID-CD is based on Central European and thus Slovenian local and traditional cuisine.
Interventions
OTHERALICALM (75% of daily caloric requirements)
PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
OTHERALICALM (100% of daily caloric requirements)
EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
Sponsors
University Medical Centre Ljubljana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Children (4 - 18 years of age) * Young adults (\>18 and ≤ 30 years of age) with childhood-onset CD (the diagnosis of CD before 18 years of age) * Assured diagnosis of Crohn's disease according to the Porto criteria * Patients with Active CD (Pediatric Crohn's Disease Activity Index (PCDAI) ≥10 in children or Harvey-Bradshaw Index (HBI) \>3 in young adults ) * Patients with new-onset CD and patients with active disease despite stable doses of concomitant therapy with immunomodulators (thiopurines, methotrexate, tacrolimus) for ≥ 3 months, on stable doses of biologic therapy (anti-TNF-a agents) for ≥ 2 months * Patients will not be excluded if they start therapy with thiopurine concurrently, as thiopurines are not considered sufficient to induce remission in active disease before 8 weeks * Written consent of the patient and/or the legal guardian
Exclusion criteria
* Patients with no disease activity ( PCDAI \<10) * Patients who have received corticosteroids of any kind in the previous 4 weeks. * Patients with penetrating disease (abscess or fistula) * Active Perianal disease * Active Extraintestinal disease * Sclerosing Cholangitis * Patients with fixed stricture or small bowel obstruction * If the patients had received any other medication for inducing remission such as steroids and/or antibiotics * No consent of the patient and/or the legal guardian
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Remission | 6 weeks | Clinical Remission (Pediatric Crohn's Disease Activity Index \<10) on an intention to treat principle after 6 weeks of therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mucosal healing | 6-8 weeks | Mucosal healing using the Simple Endoscopic Score for CD (SES-CD) |
| Change in SES-CD | At week 0 and 6 -8 weeks following enrollment | Change in SES-CD from baseline to 6 weeks |
| Changes in specific blood tests | At the 1, 3 and 6 weeks visits | Changes in specific blood tests such as erythrocyte sedimentation rate (ESR), C reactive protein, hemoglobin, albumin, and platelets from baseline to 6 weeks |
| Clinical response | 6 weeks | \- Clinical response defined as a decrease in Pediatric Crohn's Disease Activity Index score of ≥12.5 points) for children or a drop in HBI of at least 2 points in young adults |
| Changes in weight-z-scores | At the 0 and 6 weeks visits | Changes in weight-z-scores |
| Changes in ITM -z-scores | At the 0 and 6 weeks visits | Changes in ITM -z-scores |
| Changes in stool calprotectin concentrations | At the 3 and 6 weeks visits | Changes in stool calprotectin concentrations (mg/kg) from baseline to 6 weeks |
Countries
Slovenia
Contacts
Primary ContactDarja Urlep, MD, MSc
Backup ContactEvgen Benedik, PhD
Outcome results
None listed